BNN logo

BRAIN Biotech AG Stock Price

XTRA:BNN Community·€51.1m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

BNN Share Price Performance

€2.34
-0.92 (-28.22%)
€6.50
Fair Value
€2.34
-0.92 (-28.22%)
64.0% undervalued intrinsic discount
€6.50
Fair Value
Price €2.34
AnalystHighTarget €6.50

BNN Community Narratives

AnalystHighTarget·
Fair Value €6.5 64.0% undervalued intrinsic discount

Enzyme Shift And BioIncubator Optionality Will Support Stronger Long Term Outcomes

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
€6.5
64.0% undervalued intrinsic discount
Revenue
12.07% p.a.
Profit Margin
5.22%
Future PE
45.7x
Price in 2029
€7.72

Trending Discussion

Updated Narratives

BNN logo

Enzyme Shift And BioIncubator Optionality Will Support Stronger Long Term Outcomes

Fair Value: €6.5 64.0% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Slight risk and slightly overvalued.

4 Risks
2 Rewards

BRAIN Biotech AG Key Details

€50.2m

Revenue

€22.1m

Cost of Revenue

€28.1m

Gross Profit

€39.8m

Other Expenses

-€11.7m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 25, 2026
-0.54
55.95%
-23.38%
637.2%
View Full Analysis

About BNN

Founded
1993
Employees
292
CEO
Adriaan Moelker
WebsiteView website
www.brain-biotech.com

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

Recent BNN News & Updates

Analysts Have Been Trimming Their BRAIN Biotech AG (ETR:BNN) Price Target After Its Latest Report

Jan 18
Analysts Have Been Trimming Their BRAIN Biotech AG (ETR:BNN) Price Target After Its Latest Report

Recent updates

No updates